375
We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.
 a patient with acute promyleocytic leukemia (APL): Subject; scrotal ulcer: Effect; within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily: Treatment; within 10 days: Treatment.Time_elapsed; ATRA: Treatment.Drug; 40 mg: Treatment.Dosage; orally: Treatment.Route; twice daily: Treatment.Freq; acute promyleocytic leukemia (APL): Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with acute promyleocytic leukemia (APL): Subject; scrotal ulcer: Effect; within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily: Treatment; within 10 days: Treatment.Time_elapsed; ATRA: Treatment.Drug; 40 mg: Treatment.Dosage; orally: Treatment.Route; twice daily: Treatment.Freq; acute promyleocytic leukemia (APL): Treatment.Disorder